Genmab is an international biotechnology company specializing in the creation and development of differentiated human antibody therapeutics for the treatment of cancer.

Envisioning the Future of Cancer Treatment: A Video with CEO Jan van de Winkel

Genmab's CEO shares his perspective on how the company's work to develop innovative antibody therapeutics could change the lives of cancer patients in the future.  Click here to watch the video.

Genmab Opens Doors to Innovation

Genmab is inviting researchers in academia and industry to experience the full power of the DuoBody® platform for bispecific antibody research and drug development. Explore the possibilities via our recently published Perspective in the journal mAbs and the renewed Open Innovation section on

Visit Our Download Library

Access our latest presentations and posters including daratumumab data presented at ASCO and our investor presentation at the Jefferies 2014 Global Healthcare Conference in our Download Library.

Latest news


  • At the heart of Genmab is a deep desire to improve the quality of life for cancer patients.
  • Click here to watch our video about our fight against cancer.


Stock Price as of 07/28/2014 12:00 AM (CET)

  • Share Price DKK 215.70
  • Change (in DKK) -3.80
  • Volume 123385

Stock Information